Epstein-Barr Virus

Grafts In EBV-Infected Patients Rejected Due To Immunosuppression

Published in Hepatitis Weekly, April 9th, 2001

by Sonia Nichols, staff medical writer - Although liver transplant patients with Epstein-Barr virus (EBV) can be treated with immunosuppressive therapies, their long-term prospects for graft survival are not good, scientists say.

Investigators at the University of Pittsburgh Medical Center in Pennsylvania studied biopsy samples from more than 20 patients with EBV-associated primarily extrahepatic post-transplant lymphoproliferative disease (PTLD).

Almost all of the patients showed signs of acute rejection in liver biopsies, with only four of 24 patients demonstrating no signs of rejection, according to investigators.

"EBV...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-04-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry